Merck has announced that WINREVAIR® (sotatercept) is now authorized for use in Canada in combination with standard pulmonary arterial hypertension (PAH) therapy. This marks a significant advancement, introducing the first activin signaling inhibitor therapy for PAH patients in Canada.
This milestone is, in part, the result of our ongoing advocacy efforts alongside the work of many dedicated individuals and organizations. We submitted a letter to Health Canada urging them to prioritize this treatment, and earlier this year, we gathered in Ottawa for World PH Day to meet with officials and raise awareness of the urgent need for improved care. Additionally, our nationwide survey led to the report, The Socioeconomic Burden of PAH in Canada, which highlighted the ongoing challenges faced by PAH patients.
Comments